Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EMERALD: Rosuvastatin for Lipid Disorders in the Emergency Department
NCT05742841Phase 4Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Mar 2023
- Primary completion
- Jun 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 4 trial of rosuvastatin in hyperlipidemia, sponsored by Wake Forest University Health Sciences. Started Mar 2023; status: completed.
02
Drugs
rosuvastatin
03
Conditions
hyperlipidemia
Beyond the preview
Go deeper on NCT05742841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05742841.